Interview. Precision Medicine Fund Manager on Portfolio Construction, Risk, and "Developers" vs "Enablers"
In this insightful interview with Blue Box Asset Mangement's Porfolio Manager Mark Dainty we talk about precision medicine and life sciences, his investment strategy, and how he constructs a portfolio of "developers" vs "enablers". We also talk about 3 stocks in the fund. We hope you enjoy listening!
*~*~*~*~*
Get access to all of Speedwell Research's in-depth Research Reports here.
If you need help getting Speedwell added as an approved research vendor for your investment firm, please reach out to info@speedwellresearch.com
-*-*-*-*-*-*-*-*-*-*-
Show Notes
(0:00) — What is Precision Medicine and Life Sciences
(11:15) — Small Markets, but Higher Prices
(22:24) — Why Precision Medicine is like Dating Apps
(27:56) — Investment Strategy and Portfolio Construction
(47:20) — Two Stocks: Natera ($NTRA) and Guardant Health ($GH)
(54:24) — Risk of the Unknown?
(1:02:55) — Revolutions Medicines ($RVMD)
(1:11:10) — Financial Modeling
-*-*-*-*-*-*-*-*-*-*-
Become a Speedwell Member here to gain access to *all* of our in-depth research reports and more!
Sign up for Speedwell's free newsletter and weekly memos here
*~*~*~*~*
Follow Us:
Twitter: @Speedwell_LLC
Threads: @speedwell_research
Email us at info@speedwellresearch.com for any questions, comments, or feedback.
-*-*-*-*-*-*-*-*-*-*-
Disclaimer
Nothing in this podcast is investment advice nor should be construed as such. Contributors to the podcast may own securities discussed. Furthermore, accounts contributors advise on may also have positions in companies discussed. Please see our full disclaimers here: https://speedwellresearch.com/disclaimer/